Skip to main content

Mark Straley, Jan Egberts

Agendia has appointed Mark Straley its CEO, succeeding Jan Egberts, who has served as the interim CEO since October 2014. 

Straley has more than 25 years of experience in developing and commercializing clinical diagnostics and laboratory services and most recently was president, anatomical pathology at Thermo Fisher Scientific. Prior to that, he was president and CEO of Metamark Genetics. Between 2005 and 2010, Straley was worldwide vice president of marketing, and then the worldwide president of Johnson & Johnson's Ortho Clinical Diagnostics.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.